We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current RGNX market cap is 715.73M. The company's latest EPS is USD -5.9309 and P/E is -2.71.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 26.51M | 38.02M | 19.14M | 19.98M | 28.91M |
| Operating Income | -70.82M | -58.47M | -66.16M | -73.11M | -64.96M |
| Net Income | -75.48M | -59.94M | -66.68M | -72.06M | -61.87M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 35.24M | 154.57M | 470.35M | 119.4M | 90.24M |
| Operating Income | -149M | -111.26M | 157.74M | -262.88M | -268.13M |
| Net Income | -94.73M | -111.25M | 127.84M | -280.32M | -263.49M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 883.79M | 833.27M | 747.83M | 682.46M | 633.79M |
| Total Liabilities | 319.97M | 317.07M | 282.69M | 276.6M | 270.69M |
| Total Equity | 563.82M | 516.2M | 465.14M | 405.86M | 363.1M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 497.91M | 708.16M | 1.11B | 833.27M | 573.97M |
| Total Liabilities | 47.71M | 330.41M | 349.61M | 317.07M | 262.23M |
| Total Equity | 450.2M | 377.75M | 764.3M | 516.2M | 311.74M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -168.12M | -207.49M | -80.92M | -128.24M | -177.65M |
| Investing | -38.63M | -11.93M | 63.09M | 118.31M | 156.97M |
| Financing | -19.92M | -28.84M | -9.04M | -18.2M | -23M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -107.71M | -54.06M | 218.88M | -207.49M | -218.41M |
| Investing | 93.56M | 122.76M | -406.64M | -11.93M | 190.94M |
| Financing | 8.38M | 200.21M | 195.25M | -28.84M | -34.97M |
| Market Cap | 715.73M |
| Price to Earnings Ratio | -2.71 |
| Price to Sales Ratio | 7.92 |
| Price to Cash Ratio | 20.69 |
| Price to Book Ratio | 2.29 |
| Dividend Yield | - |
| Shares Outstanding | 44.43M |
| Average Volume (1 week) | 391.1k |
| Average Volume (1 Month) | 449.63k |
| 52 Week Change | -17.17% |
| 52 Week High | 28.80 |
| 52 Week Low | 11.83 |
| Spread (Intraday) | 1.91 (10.66%) |
| Company Name | REGENXBIO Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.regenxbio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
